Skip to main content
Erschienen in: International Journal of Hematology 1/2017

24.08.2016 | Original Article

Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia

verfasst von: Julie Waisbren, Shira Dinner, Jessica Altman, Olga Frankfurt, Irena Helenowski, Juehua Gao, Brandon J. McMahon, Brady L. Stein

Erschienen in: International Journal of Hematology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Patients with myelodysplastic syndrome (MDS) who present with isolated thrombocytopenia (TCP) constitute a poorly described subgroup. The aim of the present study was to retrospectively evaluate disease characteristics and prognosis in patients with MDS and isolated TCP at a tertiary care center. Fifty patients (12 %) had isolated thrombocytopenia as the first presentation of MDS. Patients had varying MDS sub-classifications and cytogenetic profiles. The most common IPSS-R risk score was low (n = 24), although half of the patients had either IPSS-R intermediate (n = 18), high or very high risk disease (n = 7). Leukemic transformation occurred in 10 patients and there were 14 deaths (28 %) amongst all IPSS-R risk scores. Therapeutic agents used in this patient subgroup included hypomethylating agents and thrombopoietin receptor agonists. Overall, MDS with isolated TCP did not appear to have an inherently indolent course, as has been suggested previously. Future studies are needed to improve risk stratification, identify relevant contributors to disease pathogenesis, and better define treatment modalities.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001;73(4):405–10.CrossRefPubMed Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001;73(4):405–10.CrossRefPubMed
3.
Zurück zum Zitat Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014;124(18):2793–803.CrossRefPubMed Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014;124(18):2793–803.CrossRefPubMed
4.
Zurück zum Zitat Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006;81(1):104–30.CrossRefPubMed Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006;81(1):104–30.CrossRefPubMed
5.
Zurück zum Zitat Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med. 2012;125(7 Suppl):S6–13.CrossRefPubMed Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med. 2012;125(7 Suppl):S6–13.CrossRefPubMed
6.
Zurück zum Zitat Qian J, Xue Y, Pan J, Cen J, Wang W, Chen Z. Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura. Int J Hematol. 2005;81(2):142–7.CrossRefPubMed Qian J, Xue Y, Pan J, Cen J, Wang W, Chen Z. Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura. Int J Hematol. 2005;81(2):142–7.CrossRefPubMed
7.
Zurück zum Zitat Mainwaring CJ, Shutt J, James CM. Not all cases of idiopathic thrombocytopenic purpura [correction of pupura] are what they might first seem. Clin Lab Haematol. 2002;24(4):261–2.CrossRefPubMed Mainwaring CJ, Shutt J, James CM. Not all cases of idiopathic thrombocytopenic purpura [correction of pupura] are what they might first seem. Clin Lab Haematol. 2002;24(4):261–2.CrossRefPubMed
8.
Zurück zum Zitat Kuroda J, Kimura S, Kobayashi Y, Wada K, Uoshima N, Yoshikawa T. Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. Acta Haematol. 2002;108(3):139–43.CrossRefPubMed Kuroda J, Kimura S, Kobayashi Y, Wada K, Uoshima N, Yoshikawa T. Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. Acta Haematol. 2002;108(3):139–43.CrossRefPubMed
9.
Zurück zum Zitat Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. Cancer. 1989;64(12):2506–10.CrossRefPubMed Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. Cancer. 1989;64(12):2506–10.CrossRefPubMed
10.
Zurück zum Zitat Hwang Y, Huh JW, Mun YC, Seong CM, Chung WS. Myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura. Korean J Lab Med. 2010;30(2):105–10.CrossRefPubMed Hwang Y, Huh JW, Mun YC, Seong CM, Chung WS. Myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura. Korean J Lab Med. 2010;30(2):105–10.CrossRefPubMed
11.
Zurück zum Zitat Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol. 2007;139(2):265–8.CrossRefPubMed Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol. 2007;139(2):265–8.CrossRefPubMed
12.
Zurück zum Zitat Menke DM, Colon-Otero G, Cockerill KJ, Jenkins RB, Noel P, Pierre RV. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol. 1992;98(5):502–10.CrossRefPubMed Menke DM, Colon-Otero G, Cockerill KJ, Jenkins RB, Noel P, Pierre RV. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol. 1992;98(5):502–10.CrossRefPubMed
13.
Zurück zum Zitat Sashida G, Takaku TI, Shoji N, et al. Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. Leuk Lymphoma. 2003;44(4):653–8.CrossRefPubMed Sashida G, Takaku TI, Shoji N, et al. Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. Leuk Lymphoma. 2003;44(4):653–8.CrossRefPubMed
14.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.CrossRefPubMed Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.CrossRefPubMed
15.
Zurück zum Zitat Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–25.CrossRefPubMed Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–25.CrossRefPubMed
16.
Zurück zum Zitat Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88.PubMed Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88.PubMed
17.
Zurück zum Zitat Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.CrossRefPubMedPubMedCentral Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.CrossRefPubMedPubMedCentral Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Mitsutani S, Kohriyama T, Kamio M, Saitoh T. Isolated thrombocytopenia as presenting symptoms of myelodysplastic syndromes. [Rinsho ketsueki] Jpn J Clin Hematol. 1987;28(6):945–50. Mitsutani S, Kohriyama T, Kamio M, Saitoh T. Isolated thrombocytopenia as presenting symptoms of myelodysplastic syndromes. [Rinsho ketsueki] Jpn J Clin Hematol. 1987;28(6):945–50.
20.
Zurück zum Zitat George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.PubMed George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.PubMed
21.
Zurück zum Zitat Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.CrossRefPubMed Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.CrossRefPubMed
22.
Zurück zum Zitat Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. New Engl J Med. 2011;364(26):2496–506.CrossRefPubMedPubMedCentral Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. New Engl J Med. 2011;364(26):2496–506.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bacher U, Haferlach T, Schnittger S, et al. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br J Haematol. 2014;164(6):822–33.CrossRefPubMed Bacher U, Haferlach T, Schnittger S, et al. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br J Haematol. 2014;164(6):822–33.CrossRefPubMed
24.
Zurück zum Zitat Gao J, Gentzler RD, Timms AE, et al. Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature. J Hematol Oncol. 2014;7:36.CrossRefPubMedPubMedCentral Gao J, Gentzler RD, Timms AE, et al. Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature. J Hematol Oncol. 2014;7:36.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010;10:401.CrossRefPubMedPubMedCentral Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010;10:401.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(21):2671–7.CrossRef Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(21):2671–7.CrossRef
27.
Zurück zum Zitat Neukirchen J, Lauseker M, Blum S, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res. 2014;38(1):57–64.CrossRefPubMed Neukirchen J, Lauseker M, Blum S, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res. 2014;38(1):57–64.CrossRefPubMed
28.
Zurück zum Zitat Prica A, Sholzberg M, Buckstein R. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol. 2014;167(5):626–38.CrossRefPubMed Prica A, Sholzberg M, Buckstein R. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol. 2014;167(5):626–38.CrossRefPubMed
29.
Zurück zum Zitat Oliva EN. Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim results on efficacy, safety and quality of life of an international, multicenter prospective, randomized, trial. American Society of Hematology 57th annual meeting and exposition; Orlando; December 5–8, 2015. Oliva EN. Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim results on efficacy, safety and quality of life of an international, multicenter prospective, randomized, trial. American Society of Hematology 57th annual meeting and exposition; Orlando; December 5–8, 2015.
Metadaten
Titel
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia
verfasst von
Julie Waisbren
Shira Dinner
Jessica Altman
Olga Frankfurt
Irena Helenowski
Juehua Gao
Brandon J. McMahon
Brady L. Stein
Publikationsdatum
24.08.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 1/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2081-4

Weitere Artikel der Ausgabe 1/2017

International Journal of Hematology 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.